In a bold new trade move, President Donald Trump has announced sweeping U.S. import tariffs on several major product categories — including 100% duties on branded pharmaceuticals, 25% tariffs on heavy-duty trucks, and up to 50% on imported furniture.

The administration says these new tariff hikes aim to protect U.S. manufacturers, bolster national security, and reduce reliance on foreign supply chains. But critics warn the move could drive consumer prices higher, worsen global trade tensions, and fuel inflation just as the economy is seeking stability.

The biggest headline-grabber is a 100% import tariff on branded prescription drugs produced outside the U.S. The tariff will apply only to companies that haven’t yet built or begun domestic manufacturing facilities.

Trump argued that critical medicine production should be done within U.S. borders for reasons of national security and price stability.

Pharmaceutical giants like Roche and Novartis have already announced multi-billion-dollar U.S. investments to get ahead of these measures. But analysts warn that short-term impacts may include supply chain disruptions and rising drug prices for American consumers.

The new tariff package also introduces:

Trump framed the move as a way to revitalize American manufacturing, saying the U.S. must “bring back the furniture business” and protect domestic auto and trucking industries.

But trade associations are pushing back. The U.S. Chamber of Commerce warned the tariffs could raise logistics costs, while the Vietnam Furniture Association called the move “unfair,” noting it could disrupt global supply chains.

In 2024, 60% of U.S. furniture imports came from Vietnam and China, and the majority of truck imports originated from Mexico, Japan, Canada, and Germany — all key allies.

Asian markets fell sharply following the announcement, especially among pharma and manufacturing stocks. European indices initially dipped but recovered as investors waited for clarity on exemptions and scope.

In the U.S., markets appeared largely unfazed. Analysts from BMO Economics noted that investors remain in a “wait-and-see” mode, expecting limited short-term impact unless consumer spending or inflation worsens.

Economists, however, caution that renewed trade tensions could complicate Federal Reserve efforts to curb inflation. The Fed has previously linked Trump’s tariff policies to higher consumer costs and economic uncertainty.

The new measures also carry political and legal implications. The Trump administration is seeking stronger legal footing for its trade policies as the Supreme Court reviews a case challenging the scope of presidential tariff authority.

By focusing on national security and American jobs, Trump is reinforcing his “America First” trade platform — a key pillar of his 2026 re-election campaign.

The European Commission signaled concern, pointing to trade agreements capping tariffs at 15%. Japan also stressed that its bilateral deal with the U.S. limits tariff hikes.

In Ireland, where U.S. pharmaceutical firms account for 2% of the workforce, exports to America surged 536% year-over-year — as companies rushed to ship goods ahead of the October 1 deadline.

Starting October 1, 2025, consumers may see rising prices on prescription drugs, furniture, and vehicles. Small U.S. manufacturers could benefit from reduced foreign competition, but retailers and transport companies face higher input costs.

The ripple effects could spread across housing, healthcare, and transportation sectors, increasing inflationary pressures even as the White House pledges to keep prices down.

President Trump’s new tariff strategy marks another escalation in his protectionist trade agenda. While intended to rebuild U.S. industry, the policy could spark new trade conflicts, raise costs for households, and reshape global supply chains.

For years, buying cannabis meant taking a trip to a dispensary, dealing with long lines, limited selection, and inconsistent pricing. But thanks to changing laws and innovative online retailers, buying high-quality THC products is now 100% federally legal—and more convenient than ever.

And when it comes to quality and reliability, Mood is leading the way…

Because they’ve completely flipped the script on cannabis shopping. Instead of memorizing hundreds of confusing strain names – like “Gorilla Glue” and "Purple Monkey Breath" – you simply choose how you want to feel: Creative, Social, Focused, Relaxed, Happy, Aroused, and more.

Each gummy is formulated with the perfect blend of Delta-9 THC and botanicals to deliver the perfect mood.

Want a great night’s sleep? Try the Sleepytime gummies. Need laser focus Mind Magic gummies have you covered. Hotter sex? Try the Sexual Euphoria gummies.

It's cannabis shopping that actually makes sense for “normal” people.

20% OFF your first order!